



Financial Tear Sheet

Corporate Profile

Codexis, Inc. (Nasdaq: CDXS), is a leading developer of biocatalysts for the pharmaceutical and fine chemical industries. Codexis utilizes its proprietary CodeEvolver® directed evolution technology platform and CodeXporter® enzyme production platform, for the discovery, identification, optimization, and efficient production of enzymes for its customers. Customers include global leaders such as Merck, Pfizer and Teva. For more information, see www.codexis.com

Stock Performance

CDXS (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	\$5.30
Change (%)	▲ 0.05 (0.95%)
Volume	74,606
52 Week Low	\$3.60
Market Cap	\$256,119,357
Rolling EPS	-0.40
PE Ratio	N/A
Shares Outstanding	48,324,407

Data as of 08/16/17 4:00 p.m. ET



Recent News Releases

August 09, 2017

[Codexis Reports Financial Results for the Second Quarter of 2017](#)

Upcoming Events

There are currently no events scheduled.

SEC Filings

	Filing Date	Form
August 08, 2017		
<u>Codexis Obtains Court Order Awarding Summary Judgment of Patent Infringement against EnzymeWorks</u>	08/09/17	10-Q
	08/09/17	8-K
August 02, 2017	07/07/17	8-K
<u>Codexis to Hold 2017 Second Quarter Conference Call on August 9</u>	06/16/17	4

Powered By **EDGAR** Online

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Minimum 20 minutes delayed